Analysis of immune cells at the tumor implantation site 3 weeks after intracranial injection of the tumor cells revealed a significantly higher percentage of CD8+ T cells in the four mice in the combination therapy group that had rejected tumors for the second time as compared to the control represented by the mice in which there was tumor re-growth (Figure 2d,e). The gene discussed is CD8A; the disease is neoplasm.